evidence: Prescribing clinicians and eye care specialists share responsibility for safely prescribing hydroxychloroquine (HCQ) and screening for the potential risk of retinopathy. Two relevant national societies, the American College of Rheumatology (ACR) and the American Academy of Ophthalmology (AAO), have independently offered management guidelines (1, 2), but this is the first joint statement to emphasize points of agreement that should be recognized by practitioners in all specialties. The ACR and AAO are joined in this statement with the American Academy of Dermatology (AAD) and Rheumatologic Dermatology Society (RDS) [...] This consensus opinion is limited by the relative dearth of data on dosage of hydroxychloroquine required to achieve clinical benefit, the lack of prospective data on toxicity, the need for additional studies on the value of blood levels in achieving efficacy or avoiding toxicity, and the need for pharmacogenomic studies that might identify those at greater (or lesser) risk.